The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Related to this article
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
2
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
3
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
4
China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC
5